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Cell-to-cell communication via gap junctions has been proposed to be involved in the metabolic actions of sympathetic liver nerves in the rat, The 
effects of hcpatic nerve stimulation and noradrenaline-, PGF> - and glucagon infusion on glucose metabolism and perfusion flow were studied in 
perfused rat liver in the absence and presence of the gap junctional inhibitors, hcptanol, carbenoxolonc and (4fi)phorbol 12myristate 13.acetate 
(4PPMA). (i) Stimulation of the hepatic nerve plexus increased glucose output, decreased flow and caused an overflow of noradrenaline into the 
hepatic vein. (ii) Heptanol completely inhibited not only the nerve stimulation-dependent metabolic and hemodynamic alterations but also the 
noradrenaline overflow. Thus the heptanol-dependent i hibitions were caused primarily by a strong impairment of transmitter elease. (iii) 
Carbenoxolone inhibited the effects of ncurostimulation on glucose metabolism partially by about 50%. whereas it left perfusion flow and 
noradrenaline overflow essentially unaltered. (iv) 4bPMA reduced the nerve stimukdtion-dependent enhancement of glucose release by about 80% 
but the noradrenaline-dependent increase in glucose output only by about 30%; the increase in glucose release by PGF:. and by glumgon remained 
essentially unaltered, 4pPMA reduced the nerve stimulation-dependent decrease in portal flow by about 35% but did not affect he noradrenalinc- 
and PGFh-elicited alterations, nor did it alter noradrenaline overtlow. The results allow the conclusion that gap junctional communication plays 
a major role in the regulation of hepatic arbohydrate metabolism by sympathetic liver nerves, but not by circulating noradrenaline. PGF, or 
glucagon. 
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1. INTRODUCTION 
The liver is innervated by sympathetic and parasym- 
pathetic nerves, containing efferent and afferent fibres. 
The vegetative nerves reach the liver via the anterior 
plexus around the hepatic artery and the posterior 
plexus around the portal vein [l-S]. Noradrenaline and 
adrenaline, released from peripheral synapses via over- 
flow and from the adrenals, respectively, also reach the 
organ with the circulating blood; they could act via a,-, 
CQ- and p-receptors [6,7]. 
In perfused rat liver, stimulation of the nerve plexus 
around the portal vein and the hepatic artery caused an 
increase in glucose and lactate output [6-101 and urate 
and allantoin formation [ll], a decrease in ketogenesis 
[12], urea release and ammonia uptake [13] as well as 
oxygen utilization [14,15]. Furthermore, nerve stimula- 
tion decreased [6-lo] and redistributed [I S] flow ihtra- 
hepaticly and caused an overflow of noradrenaline into 
the hepatic vein [6,7,16]. All nerve actions required ex- 
tracellular calcium [8,17J. Noradrenaline released by 
nerve stimulation from the nerve endings 1161 acted via 
sympathetic al-receptors [6,71. Since inhibitors of pro- 
stanoid synthesis inhibited the nerve actions [13] and 
since prostaglandins mimicked these actions [ 191, it was 
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proposed that prostaglandins like PGFI, released from 
non-parenchymal cells served as ‘inter-transmitters’ in 
the nervous ignal chain [19]. Noradrenaline and pro- 
stanoids caused the alteration in metabolism and hemo- 
dynamics via their specific receptors [20-231. 
It was found that the content of noradrenaline in liver 
tissue and the amounts released upon nerve stimulation 
were much higher in livers of guinea pig and tree shrew 
than in rat [24]. These findings were in line with anatom- 
ical observations that in guinea pig and tree shrew 
nearly all liver cells possess nerve contacts while in the 
rat only a few periportal cells are innervated [25,26]. 
Since the carbohydrate metabolism in guinea pig and 
tree shrew liver was regulated by nerve stimulation sim- 
ilarly to rat liver [24], a mechanism had to be postulated 
which would compensate the rare hepatic innervation 
in rat liver and thereby cause the same effective activa- 
tion of glycogenolysis as in guinea pig and tree shrew 
liver. Thus, it was proposed that the nerve signal is 
propagated through gap junctions via electrotonic ou- 
pling [8,9,2426]. 
It was the object of the present investigation to study 
the role of gap junctions in the nervous signal chain in 
the perfused rat liver by using gap junctional inhibitors. .
Various substances such as heptanol [27-301, glycyr- 
rhetinic acid derivatives like carbenoxolone [3 1,321 and 
(4@)phorbol IZmyristate 13-acetate (4,f?PMA) [29, 
30,33,34] have been reported to cause closure of gap 
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junctions in a variety of cell systems [27-341. It was 
found that heptanol completely inhibited the metabolic 
and hemodynamic nerve, actions but also the noradren- 
aline overflow, while carbenoxolone and PMA im- 
paired the metabolic nerve effects without modifying 
noradrenaline overflow. The present results allow the 
conclusion that gap junctions are involved in the signal 
chain of sympathetic metabolic nerve action in rat liver. 
While this work was in progress, a study appeared 
which came to the same conclusion using a quite differ- 
ent approach [35]. 
2. MATERIALS AND METHODS 
All chemicals were of reagent grade and from colnmercial sources. 
Enzymes, cocnzymes. ubstrates and bovine serum albumin were pur- 
chased from Boehringer (Mannheim, Germany), except plucose dehy 
drogcnase, which was from Merck (Darmstadt, Germany). I-Norad- 
renaline bitartratc and glucagon were from Serva (Heidelberg, Ger- 
many). I-Heptanol, prostaglandin F:,, carbcnoxolonc and (4/3)phor- 
bol I’-myristate 13-acetate (4BPMA) were purchased frcm Sigma 
(Dciscnhofen, Germany), 
Male Wistar rats (220-300 g) were obtained from Winkclmann 
(Borcben, Germany). At least I week before the experiments, they 
were subjected to a 12 h day-night rhythm with frtie access lo water 
and food (standard rat diet of Ssniff, Soest, Germany). All cxperi- 
menu were started between 09.00 and 10.00 h. The animals were 
anaesthetizcd by intra-peritoneal injection of pentobarbital (IUO-150 
mg/kg body weight). 
2.3. Liver pcrfksiun 
The liver was perfused in situ without recirculation via the portal 
vein in a 37’C cabinet using an erythrocyte-free Krebs-Henscleit 
bicarbonate buffer containing 5 mM glucose. 2 mM lactate. 0.2 mM 
pyruvate and 0.5% bovine serum albumin. The medium was equili- 
brated with a gas mixture of95% (v/v) 0: and 5% (v/v) COs. Perfusion 
pressure was constant at about I5 cm Hz0 with a flow rate of 3.8-4.5 
mlmin-‘,g liver”’ under basal conditions. Perfusion flow was meas- 
ured by fractionating the effluent at intervals of 0.5 min. All cxpcri- 
mcnts were started after a 30 min pre.pcrfusion. 
2.4. Nerlle stimfrrrim cm-l inftirsiou oJ‘sig& coryxwrtrls 
The hepatic nerves were stimulated (I2 V, IO Hz, 0.5 ms) with a 
bipolar platinum wire elcctrodc placed around both the portal vein 
and the hepatic artery. The latter vessel was not perfused bul still 
joined to the portal vein. Noradrenaline, P3Fti and glucagon (final 
concentration 1yM, 5 ,&l and I nM, respeztively) were dissol\,ed in 
physiological saline and then diluted to an appropriate conccntmdon 
for infusion in Krebs-Henseleit bicarbonate buffer containing 0.1% 
bovine serum albumin. The concentrntion of the stock solutions which 
were used for infusion was about 60.fold higher than the final concen- 
tration in the portal vein. 
2.5. Gup ju,lrrionnl inhibitors 
Hcptanol (final concentration 2mM) and carbenoxolone (final con- 
centration 50 yM) were added directly to the perfusion medium. 
4pPMA (final concentration IO nM) was dissolved in dimcthylsulfox- 
ide (DMSO) and then diluted to an appropriate concentration for 
infusion in Krebs-Henseleit bicarbonate buffer containing 0.1% bo- 
vine serum albumin. 
2.6. Dctermirutim of rnetubolites nnd noruhnuhc 
Metabolitcs were measured with standard enzymatic techniques: 
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glucose with glucose dchydrogenasc (Merck glucose system) [36]. 
Noradrenaline was quantitated electrochrmically atIer separation by 
HPLC using the Waters system [37]. 
2.7, Ewluutiorr 
The metabolic effects were evaluated by calculating the area under 
the curve (AUCj of the alterations in glucose balance and perfusion 
Row. When baselines of glucose balance after infusion differed from 
those of the prc-stimulation period, both baselines were connected for 
evaluation of the area under the curve as indicated in Fig, 1. Signifl- 
cancc was tested with Student’s t-test for paired or unpaired values as 
indicated. 
3. RESULTS 
3. I. Eflkcts of nerve stimubtion, norudrenaline, PGF,, 
and glucagon on hepatic metabolism and kentody- 
namics 
Rat livers were perfused in situ with an erythrocyte- 
free Krebs-Henseleit bicarbonate buffer for 65 min. He- 
patic nerves were stimulated (12 V, 10 Hz, 0.5 ms) (Fig. 
1A) and noradrenaline (1 PM), PGFI, (5 PM) and glu- 
cagon (1 nM) were infused for periods of 2 min (not 
shown). Electrical stimulation of the hepatic nerves in- 
creased glucose output, caused an overflow of norad- 
renaline into the hepatic vein and reduced porta: flow 
(Fig. IA). Similar alterations in glucose balance and in 
flow were caused by noradrenaline and PGF&,. Glu- 
cagon also increased glucose output, but had no effect 
on hepatic flow (not shown). 
3.2. Effects of nerve stimulation on hepatic metabolism 
and hen~odynarnics in the presence of gup junctional 
inhibitors 
So far, several substances such as heptanol, octanol, 
the anesthetics halothane and ephrane [29], glycyrrhe- 
tinic acid and its hydrophilic derivative carbenoxolone 
[3 1,321, phorbol esters uch as (4p)phorbol I2-myristate 
13-acetate (4pPMA) [29,30,33,34] and CO1 [29,38] have 
been found to induce closure of gap junctions in a vari- 
ety of cell systems. Since an adequate oxygen supply is 
a prerequisite for the metabolic and hemodynamic ef- 
fects of sympathetic nerve stimulation [39], it was im- 
possible to use CO2 as gap junctional inhibitor in per- 
fused liver. Thus, heptanol, carbenoxolone and 4/3?Mh 
were selected. 
3.2.f. Heptand. Heptanol (2 mM) added from the 1st 
to the 20th min of perfusion steadily enhanced basal 
glucose output (Fig. 1D) without influencing hepatic 
flow. Heptanol completely inhibited the nerve stimula- 
tion-dependent metabolic and hemodynamic alterations 
(Fig. lD, Table I) but it did not modify the changes by 
noradrenaline and glucagon (not shown). Apparently, 
the inhibitory effects of heptanol were not caused pri- 
marily by interactions with hepatocellular gap junctions 
but by effects on synapiic functions, since in the prss- 
ence of heptanol the overflow of noradrenaline was 
nearly completely suppressed (Fig. lD, Table I). 
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Fig. I. Effects of neurostimulation on hepatic glucose metabolism, portal flow and noradrenalinc overftow in the absence and presence of gap 
junction inhibitors. Livers were perfused via the portal vein without recirculation with Krebs-Henseleit bicarbonate buffer containing 5 mM 
glucose, 2mM lactate and 0.1 mM pyruvatc. Carbenoxolone, heptanol or4pPMA were added IO the final concentrationsand for the times indicated. 
The hepatic nerves were stimulated (I? V, IO Hz, 0.5 ms) for 2 min each as shown. Substrate balance is given by [concentration i  portal vein - 
concentration i  hepatic vein Wmol~ml-‘)I x flow (ml,min-‘.g“). Values are means f S.E.M. of the number of experiments given in parentheses, 
All inhibitory effects of heptanol on hepatic nerve heptanol application a second stimulation resulted in 
stimulation were found to be reversible. 3G min after the similar effects on glucose balance, perfusion flow and 
first nerve stimulation and 25 min after the cessation of noradrenaline overflow as in the controls (not shown). 
Table I 
Alteration in glucose balance, portal flow and noradrenalinc overflow by hepdtic nerve stimulation in the absence and prc!ncc of the gap junctional 
inhibitors. carboxolonc, 4pPMA and heptanol 
Parameters Alterations 
Control (313) Carbenoxolonc (313) 4#?PMA (6M) Heptanol(3/3) 
Glucose 
ymolgl 10.70 P I .32 5.87 ” 0.48** 2.27 r 1.01** 0.91 * 0.19** 
Fl?w 
- 55 ‘I 9 
;‘“-I 
-4.12 + 0.64 -2.96 2 I .28 -2.54 t I.011 -0.03 t 0.02** 
72 62 I 
Noradrenaline overflow 
LrnO’@ 
61 f 10 79 f 20 52 2 25 1.63 2 1.36** 
- 130 85 3 
Data represent the areas under the curves laken from Fig. I and are means f S.E.‘hi. oils numhr oirhpe&uents given in parentheses ($uco% 
flow/noradrenaline overflow). Statistics: Student’s f-test for unpaired values; significant dimerences tothe control values are indimted by *? c 0.05. 
+*p e 0.01. 
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3.2.2. Carbettosolone. Carbenoxolone (50 ,uM) added 
from the 1st to the 20th min of perfusion inhibited the 
stimulation-dependent i crease in glucose output by 
about 50% (Fig. 15, Table I), Higher concentrations of 
the glycyrrhetinic acid derivative (100 ,uM) did not 
cause a stronger inhibition (not shown). Carbenoxolone 
did not alter the nerve stimulation-dependent norad- 
renaline overflow and decrease in perfusion flow (Fig. 
lB, Table I). 
The inhibitory effect of carbenoxolone was almost 
completely reversible, since a second nerve stimulation 
30 min after the first stimulation and 25 min after cessa- 
tion of carbenoxolone infusion caused an only slightly 
and insignificantly weaker increase in glucose output 
than in the controls (not shown). 
flow (Fig. 1C; broken lines). Therefore, in the presence 
of 4pPMA glucose output and portal flow altered by 
nerve stimulation (Fig. IC), noradrenaline, PGFzo and 
glucagon (not shown) did not reach basal pre-stimula- 
tion values again. 4,L?PMA inhibited the nerve stimu- 
lation-dependent increase in glucose release by about 
80% (Figs. IC and 2; Table I) but did not affect norad- 
renaline overflow into the hepatic vein (Fig. IC, Table 
I). 4BPMA reduced the noradrenaline-dependent - 
hancement of glucose output by only 30% (Fig. 2), and 
had no influence on the increase in glucose release by 
PGF?, (Fig. 2) or by glucagon (not shown). 4,&PMA 
reduced the nerve stimulation-dependent decrease in 
portal flow by about 35% (Figs. 1C and 2; Table I), but 
did not alter the flow reductions caused by noradrenal- 
ine and I’GFz, (Fig, 2). 
3.2.3. (4,8) Pltorbol 12-ttzyrisrure I3-ucrture (@PMA). In an additional series of experiments it was shown 
4pPMA (10 nM) infused from the 11 th min of perfusion that the inhibitory effects of 4PPMA on glucose balance 
until the end of the experiment slightly enhanced basal and perfusion flow were not reversible. A second neu- 
glucose balance and moderately decreased perfusion restimulation 30 min after the first stimulation and 25 
6Oh PPH 
ITPUT 
p 
min after cessation of 4j3PMA did not cause any in- 
crease in glucose output and reduction of perfusion flow 
(not shown), 
Hypothesis 
Fig. 2. Noradrenaline- and nerve stimulation-dependent alterations in 
hcpatic glucose output and portal flow reduction in the presence of 
4bPMA and in regenerating liver tissue. Normal rat livers were per- 
fused and the substrate balance was determined as described in Fig. 
I A and I C. Hepatic nerves were stimulated and noradrenaline (NA, 
I PM) and prostaglandin Fu (PGF,, 5 yM) were infused rrom the 
3 1st to the 32nd min of perfusion with or without addition of 4/3PMA 
at the I lth min. Foreasier comparison data from a previous tudy nre 
shown: tqenerating rat livers were perfused 48 h after partial hcpatec- 
tomy (48 II PPH) [35], Hepatic nerves were stimulated (20 V, IO Hz, 
2 ms) and noradrennline (1 PM) was infused from the 3lst to the 40111 
min of perfusion [351. Alteralions in the absence of 4,LtPMA were set 
equal to 300%. Valuev are means (areas under the curves) k S.E,M. 
of 3 experiments (@PMA) or 4 experiments (PPH) [35]. Statistics: 
Student’s f-test for unpaired values: 'P e 0.05. 
PP 
PV PV 
, / 
c Flow Glucoss t 
Fig. 3, Hypothetical scheme ofthe signal chain from nerve stimulation 
to alteration in metabolism and hemodynamics in rat liver: signal 
propagation via gap junctions from the periportal IO the perivenous 
area. C-J. gap junctions; NE. ncrsc ending; NPC. non.psrenchymel 
cell; PC, parcnchymal cell: NA,,. synaptic noradrenaline; PGd, pros- 
taglandins in the space of Disse; P-R, prostaglandin receptor; q-R. 
q-receptor. 
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4. DISCUSSION 
It was shown in the present study with the perfused 
rat liver that three different gap junction inhibitors im- 
paired the nerve stimulation-dependent i crease in glu- 
cose output: heptano! prevented the metabolic hange 
completely, carbenoxolone lowered it by 50% and 
4pPMA by 80% (Fig. I, Table I). 
4,l. Spectpciry of the inhibitory efJccrs of hepruttoi, 
carbetzosolone and @PMA 
Heptano! is a we!!-established reversible inhibitor of 
cell-to-cell communication via gap junctions. It could 
act either directly on the junctional proteins, the con- 
nexins, or indirectly via an increase in intracellular Ca” 
or H‘ or via a perturbation of membrane fluidity 
[27,28]. The latter mechanism seems more likely. In the 
present study 2 mM heptanol totally blocked the meta- 
bolic and hemodynamic nerve actions (Fig. I, Table I). 
It probably inhibited the gap junctional functions, yet 
it also inhibited nerve terminal activity: noradrenaline 
overflow, which is the result of release and re-uptake, 
was reduced essentially to zero (Fig. I; Table I), most 
likely by preventing release rather than by increasing 
re-uptake. Thus, heptano! in the complex system of an 
intact organ was not the specific gap junction inhibitor 
that is generally believed to be. The results of the hep- 
tano! experiments do not allow any conclusion on a 
possible role of gap junctions in the metabolic actions 
of the sympathetic hepatic nerves. 
Glycyrrhetinic acid derivatives represent anovel class 
of inhibitors of gap junctional communication [3 1,321. 
They bind to mineralcorticoid and glucocorticoid recep- 
tors; it is unlikely, however, that this binding plays a 
role in the inhibition of gap junctions. Rather, it has 
been proposed that they intercalate into the plasma 
membrane and bind to the gap junction connexins in- 
ducing a conformational change which results in closure 
of the channels [32]. In the present investigation 50 PM 
carbenoxolone inhibited the metabolic nerve actions by 
50% (Fig. 1, Table I) without affecting noradrenaline 
overflow. Higher 100 yM concentrations did not cause 
a stronger inhibition. Thus, it would appear that signal 
propagation through gap junctions was involved in 50% 
of the nerve stimulation-dependent metabolic altera- 
Lions. 
Diacylglycero! and phorbo! esters such as 4pPMA 
appear to cause a protein kinase C-mediated ecrease 
in gap junctional permeability, while CAMP seems to 
elicit a protein kinase A-dependent increase 
[33,34,40,41]. Moreover, 4pPMA has been found to in- 
hitit c+receptor-dependent signal chains via a protein 
kinase C-mediated esensitization f the receptor or the 
respective G-protein [42,43]. In this study IO nM 
4/3PMA reduced the metabolic actions of nerve stimula- 
tion by 80% without affecting noradrenaline overtlow. 
Yet it lowered the effects of the al-agonist noradrenal- 
ine only by 30% and left those of prostag!andin Fzz 
unaltered (Fig. 2). A plausible xplanation of these find- 
ings is that 4/3PMA inhibited 30% of the metabolic 
nerve effects by de-sensitizing the cr,-receptors and an- 
other SO% by closing the gap junctions. Thus, again gap 
junctional communication would appear to be involved 
in 50% of the metabolic nerve actions. 
4.2. Comparison of the nerve ejfecrs iti normal, 
curbenosoione or 4pPMA rrealed iiver and in re- 
generating liver 
During the present work a study on the possible in- 
volvement of gap junctions in the action of sympathetic 
liver nerves was published using a quite different ap- 
proach [35]. The content of connexin 32, a major com- 
ponent of gap junctions in rat liver, was found to be 
decreased to 25% of the control level in regenerating 
liver 48 h after a two-thirds partial hepatectomy. The 
nerve stimulation-dependent increase in glucose output 
was lowered by 80%, while the decrease in hepatic flow 
and noradrenaline overflow remained unaltered. Yet 
the noradrenaline-elicited nhancement of glucose re- 
lease was reduced only by 30% and the decrease in flow 
was even more pronounced (Fig. 2). mese results are 
identical to those obtained in the present study with 
normal but 4pPMA-treated rat livers (Fig. 2); they are 
similar to those obtained with normal, carbenoxolone- 
treated livers. The results with the regenerating liver 
also led to the conclusion that in rat, liver gap junctions 
assist signal propagation through intercellular commu- 
nication following sympathetic nerve siimulation. 
4.3. Hyporhesis for rhe tnechuttim of acrion of sympa- 
rheric liver nerves itt the rai 
The mode! is based on the fo!!owing observations: in
rat liver, sympathetic nerves appear to innervate only 
a few parenchyma! and non-parenchyma! cells in the 
proximal periporta! zone [25,26]. Rat liver is very rich 
in gap junctions [25,26]. Metabolic and hemodynamic 
effects of the sympathetic liver nerves are mediated via 
a,-receptors [4,6,7], inhibited by inhibitors of pros- 
tanoid synthesis [18] and mimicked by prostaglandins 
but not tlrromboxanes [19]. Noradrenaline as we!! as 
prostaglandin FZo stimulate glucose release from iso- 
lated parenchymal cells via an increase in inosito! 1,4,5- 
trisphosphate and thence in glycogen phosphorylase a 
WI- 
Noradrenaline released from the nerve terminals 
binds to al-receptors on the parenchymal nd the non- 
parenchyma! cells. In the proximal parenchymal cells 
noradrenaline increases glucose release and triggers a 
signal, which is propagated through the gap junctions 
to the more distal parenchyma! cells to increase g!ucose 
output there. In the proximal non-parenchymal cells 
(sphincters) noradrenaline &its contraction and thus 
reduces inusoidal flow; in addition it causes the release 
of prostaglandins into the space of Disse. The prosta- 
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glandins in turn bind to the proslaglandin receptors on 
both the parenchymal nd non-parenchymal cells. Since 
prostaglandins released from non-parenchymal cells are 
degraded very rapidly in liver [44] they do not reach 
distal cells. In the proximal parenchymal cells, prosta- 
glandins further increase glucose release and probably 
also trigger a signal, which is propagated through gap 
junctions. In the proximal non-parenchymal cells pros- 
taglandins ‘autocatalytically’ re-inforce contraction and 
thus reduction of sinusoidal f ow. Thus the sympathetic 
nerves increase glucose release mainly in the periportal 
half of the parenchyma in line with the concept of met- 
abolic zonation [45]. 
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